{
  "id": 2716904,
  "title": "Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock",
  "url": "https://urgent.news/2026/08/21/karyopharms-kpti-big-cancer-bet-faces-a-ticking-clock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T21:20:40.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/karyopharm-kpti-big-cancer-bet-212040461.html"
  },
  "original_language": "en",
  "account": "On August 13, Karyopharm Therapeutics (NASDAQ: KPTI) presented its second-quarter earnings call, unveiling a myelofibrosis combination therapy with FDA-accelerated approval potential, along with a cash reserve to support operations until September. The company faces a $15.8 million loan payment due on September 10, which could trigger a liquidity covenant violation and default if paid without new financing. Karyopharm's primary drug candidate, selinexor paired with ruxolitinib, showed promising Phase III trial results in reducing spleen volume and improving overall survival rates. With a peak US revenue opportunity of up to $1 billion, the company plans to utilize its existing commercial infrastructure for XPOVIO to quickly move forward if approved. However, the financial outlook is concerning, with revenue falling to $33.4 million from $37.9 million a year earlier and net loss widening to $67 million. The cash balance stands at $65.4 million, which can only fund operations until September 2026. A $15.8 million term loan payment is due on September 10, and if unpaid without additional financing or a lender waiver, cash could fall below the $10 million minimum liquidity covenant, triggering a default event. Despite the challenges, Karyopharm is actively seeking financing and strategic alternatives. The market sentiment is mixed, with hedge fund ownership rising and short interest at 33.51% of the float, indicating skepticism. While the clinical upside of the combination therapy is evident, the balance sheet risk poses a significant threat to the company's survival.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}